GSK India Reports Strong Q1 Growth, Sees 24% Rise in Profit After Tax Amid Portfolio Transformation

GSK India Reports Strong Q1 Growth, Sees 24% Rise in Profit After Tax Amid Portfolio Transformation​

GlaxoSmithKline Pharmaceuticals Ltd (GSK India) has announced its financial results for the first quarter ended June 30, 2026. The company reported strong growth across both its core and innovative portfolios, reflecting progress in its portfolio transformation strategy and execution excellence.

Revenue for the quarter reached INR 924 crores, marking a 15% increase year-on-year. Profit After Tax (PAT) saw a substantial rise of 24%, reaching INR 253 crores. GSK India maintained EBITDA margins at 32%.

Segment Performance Highlights​

The General Medicines portfolio performed robustly during the quarter. Key promoted brands, including Augmentin, Ceftum, and T-Bact, successfully outperformed the market (EI >100), driven by deeper scientific engagement and omnichannel execution strategies. The Respiratory portfolio continued to progress, with Nucala (mepolizumab) benefiting many patients, while Trelegy Ellipta gained traction through new access pathways.

The Vaccines business demonstrated steady growth, securing continued leadership in the self-pay private paediatric vaccine market with Infanrix Hexa and Fluarix Tetra. In the adult vaccination space, GSK India focused on older patient cohorts with Cardiovascular and Metabolic Diseases (CVMD), resulting in high vaccinations for Shingrix (Recombinant Herpes Zoster Vaccine, Adjuvanted).

The Oncology business registered significant growth since launching its specialized therapies. Jemperli (dostarlimab) is currently a leading immunotherapy for first-line primary advanced and recurrent endometrial cancer, while Zejula (niraparib) is among the top PARP inhibitors used in the maintenance treatment of recurrent ovarian cancer.

Operational Enhancements and Pipeline Focus​

The company has made tangible progress in strengthening supply chain resilience by improving end-to-end visibility, enhancing contingency planning, and diversifying sourcing to mitigate disruptions experienced in recent periods.

Looking ahead, GSK India is preparing for several key pipeline launches. Blenrep (belantamab mafodotin), an anti-BCMA ADC therapy indicated for second-line treatment in relapsed or refractory multiple myeloma in adults, is set for launch. Furthermore, Arexvy, a vaccine designed to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV), has received marketing authorization for adults over 60 years of age and high-risk adults aged 50 to 59.

Management Commentary​

Commenting on the quarterly results, Mr. Bhushan Akshikar, Managing Director of GSK India, stated that the broad-based growth demonstrates the resilience of both the core General Medicines and Vaccines portfolios and the growing contribution of the innovative business. He attributed this success to a relentless focus on scientific excellence, effective field execution, and meaningful investments in technology and talent development. Mr. Akshikar added that with the strong innovation pipeline and future launch opportunities, the company is well-positioned to deliver sustainable growth and impact for millions of patients in India.

GLAXO Stock Price Movement​

Shares of GlaxoSmithKline Pharmaceuticals Limited settled lower today, shedding ₹0.40 or 0.02% and closing at ₹2662.3. The stock saw intraday trading range between a high of ₹2670 and a low of ₹2630, with 89,406 shares changing hands in the session.